All In Biotech

Drug Trial Radar · NCT07272902

Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication

A Randomized Ablation-based Atrial Fibrillation Rhythm Control Versus Rate Control Trial in Patients With Heart Failure and Preserved Ejection Fraction (CABANA-RAFT HF): A Pilot Study

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Jan 1, 2026

Primary completion

Oct 2027

Study completion Oct 2027

Sponsor

Lead sponsor
Nova Scotia Health AuthorityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Heart and Stroke Foundation of Canada
First posted
Dec 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is testing two different ways of treating atrial fibrillation (AF) in people who also have heart failure with mildly reduced or preserved heart function. Patients will randomly be assigned to either rhythm control using catheter ablation or rate control using medicines. The pilot phase will determine if a larger study can be successfully carried out to see which approach better improves survival, reduces hospitalizations, and enhances quality of life.

Conditions

  • Atrial Fibrillation (AF)
  • Heart Failure With Mildly Reduced Ejection Fraction
  • Heart Failure With Preserved Ejection Fraction (HFPEF)
  • Rate Control
  • Rhythm Control

Interventions

  • Catheter Ablation for Atrial FibrillationProcedure

    Participants randomized to this arm will undergo catheter ablation within 4 weeks of randomization. Pulmonary vein isolation is required; additional ablation strategies may be applied at investigator discretion. Guideline-directed medical therapy for atrial fibrillation and heart failure will also be provided.

  • Rate Control Medications (beta-blockers, calcium channel blockers, digoxin)Drug

    Participants randomized to this arm will receive pharmacologic therapy to achieve guideline-recommended heart rate control (resting HR \<80 bpm, \<110 bpm with exercise). Therapy may include beta-blockers, non-dihydropyridine calcium channel blockers, or digoxin. If adequate control is not achieved with medication, AV nodal ablation and pacing may be used. Guideline-directed medical therapy for atrial fibrillation and heart failure will also be provided.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Feasibility of Trial ConductTime frame: 12 months after randomization

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • QEII HSC

    Halifax, Nova Scotia, Canada · Recruiting

  • Hamilton Health Sciences

    Hamilton, Ontario, Canada · Recruiting

  • London Health Sciences Centre

    London, Ontario, Canada · Recruiting

  • Montreal Heart Institute

    Montreal, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.